SCHEMBL13633916

SCHEMBL13633916

Cc1ccc2cccnc2c1NS(=O)(=O)c1ccc(S(=O)(=O)c2ccccc2)s1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 13/20 0.72
NFKBIA P25963 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
RELA Q04206 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
G6PD P11413 1/20 0.46
AGTR1 P30556 1/20 0.46
METAP2 P50579 1/20 0.46
METAP1 P53582 1/20 0.46
GLO1 Q04760 1/20 0.46
PAX8 Q06710 1/20 0.46
ATM Q13315 1/20 0.46
MMP2 P08253 1/20 0.46
TYMS P04818 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633852 0.86 SLC40A1 (0.67) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL11972869 0.84 SLC40A1 (1.00) SLC40A1NFKBIATDP1KMT2AALDH1A1
SCHEMBL13633769 0.82 SLC40A1 (0.70) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633842 0.82 NFKBIA (0.68) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633824 0.82 SLC40A1 (0.68) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633768 0.82 SLC40A1 (0.61) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633855 0.77 NFKBIA (0.67) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633912 0.77 GABRA1 (0.59) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633883 0.76 SLC40A1 (0.54) SLC40A1NFKBIATDP1RELAMEN1
SCHEMBL13633878 0.76 SLC40A1 (0.59) SLC40A1NFKBIATDP1RELAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A SLC40A1 4638/4885NFKBIA 980/4885TDP1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.